TP53 and cancer: In view of the high penetrance for cancers, published guidelines recommend that “heterozygotes” or carriers of TP53 GPV to undergo yearly cancer surveillance from birth comprised of whole body (WB) + brain (B) magnetic resonance imaging (MRI) alongside breast MRI (for women over 20 years who have not undergone risk-reducing mastectomy), annual clinical review and skin examination [2–4].